Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
February 08 2021 - 7:30AM
Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company
focused on advancing innovative life-transforming therapeutics for
people living with genetically driven diseases, today announced the
appointment of Ashish Dugar, Ph.D., MBA, as senior vice president,
global head of medical affairs. Dr. Dugar brings over 20 years of
broad experience across medical affairs, clinical and commercial
development, and real-world evidence (RWE) generation.
“We are thrilled to welcome Ash to the Dyne team
and he’ll play an instrumental role in our efforts to develop
life-transforming therapies for patients. He has deep experience
across clinical, commercial, patient advocacy, RWE,
and market access with leading drug development
companies and proven success in building a global medical affairs
organization in rare muscle disease,” said Joshua Brumm, president
and chief executive officer of Dyne. “Ash is representative of the
exceptional talent we have been fortunate to attract to Dyne
as we execute on our vision of building the world’s leading muscle
disease company.”
Prior to joining Dyne, Dr. Dugar served as vice
president and global head of medical affairs at Sarepta
Therapeutics, Inc., where he built the company’s medical affairs
organization. Previously, he led all commercial and market access
efforts for Intra-Cellular Therapies, Inc. as vice president and
head of commercial development. Dr. Dugar joined Intra-Cellular
Therapies following his tenure at Roche, where he was global head
of clinical development science and innovation and global head of
the external development group, including work in oligonucleotides.
Previously, he spent 13 years at Pfizer Inc. in various roles, most
recently serving as vice president, global head of clinical
development and medical affairs of the biosimilars business unit.
Dr. Dugar began his career at the National Institutes of Health. He
completed a pharmacoeconomics and outcomes research fellowship at
the University of Michigan School of Public Health. Dr. Dugar
earned an MBA from The Pennsylvania State University and a Ph.D. in
pharmacology from The Pennsylvania State University College of
Medicine.
“Dyne is leading a novel approach to solving
historical challenges in the development and delivery of modern
oligonucleotide therapies for rare muscle diseases, an area I’m
incredibly passionate about given the vast unmet patient need. With
platform-validating preclinical data and the opportunity to deliver
first- and best-in-class therapies at a company with a strong
culture focused on innovation and excellence in execution, I am
excited to join the team at this pivotal time. Dyne is well
positioned for success as we work to advance our three
programs into clinical trials,” said Dr. Dugar.About Dyne
TherapeuticsDyne Therapeutics is building a leading muscle
disease company dedicated to advancing innovative life-transforming
therapeutics for people living with genetically driven
diseases. With its proprietary FORCE™ platform, Dyne is
developing modern oligonucleotide therapeutics that are designed
to overcome limitations in delivery to muscle tissue seen with
other approaches. Dyne’s broad portfolio of therapeutic
candidates for serious muscle diseases includes programs for
myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy
(DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more
information, please visit https://www.dyne-tx.com/, and follow
us on Twitter, LinkedIn and Facebook.
Forward-Looking StatementsThis
press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, contained in this press
release, including statements regarding Dyne’s strategy, future
operations, prospects, plans, objectives of management,
the expected timeline for submitting investigational new drug
applications, the potential advantages of Dyne’s FORCE platform and
programs, expectations regarding the translation of
preclinical findings to human disease and plans to conduct
additional preclinical studies, constitute forward-looking
statements within the meaning of The Private Securities
Litigation Reform Act of 1995. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,”
“might,” “objective,” “ongoing,” “plan,” “predict,” “project,”
“potential,” “should,” or “would,” or the negative of these terms,
or other comparable terminology are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Dyne may
not actually achieve the plans, intentions or expectations
disclosed in these forward-looking statements, and you should not
place undue reliance on these forward-looking statements.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in these
forward-looking statements as a result of various important
factors, including: uncertainties inherent in the identification
and development of product candidates, including the conduct
of research activities, the initiation and completion of
preclinical studies and clinical trials; uncertainties as to the
availability and timing of results from preclinical studies;
the timing of and Dyne’s ability to submit and obtain regulatory
approval for investigational new drug applications; whether results
from preclinical studies will be predictive of the results of
later preclinical studies and clinical trials; Dyne’s ability to
obtain sufficient cash resources to fund the Company’s
foreseeable and unforeseeable operating expenses and capital
expenditure requirements; the impact of the COVID-19 pandemic on
Dyne’s business and operations; as well as the risks and
uncertainties identified in Dyne’s filings with the Securities and
Exchange Commission (SEC), including the Company’s most recent
Form 10-Q and in subsequent filings Dyne may make with the SEC. In
addition, the forward-looking statements included in this
press release represent Dyne’s views as of the date of this
press release. Dyne anticipates that subsequent events and
developments will cause its views to change. However, while
Dyne may elect to update these forward-looking statements at some
point in the future, it specifically disclaims any obligation to
do so. These forward-looking statements should not be relied
upon as representing Dyne’s views as of any date subsequent to the
date of this press release.Contact:Dyne
TherapeuticsAmy Reillyareilly@dyne-tx.com 857-341-1203
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From Jul 2023 to Jul 2024